Gastrointestinal Cancer | Specialty

PD-1 Inhibitors for Advanced Gastroesophageal Cancer

July 18th 2018

RAINBOW Study: Antiangiogenic Therapy in Gastric Cancer

July 18th 2018

Second-line Treatment for Recurrent or Progressive GEC

July 18th 2018

Guidelines for Metastatic Frontline Therapy in GEC

July 18th 2018

Improving Surgical Outcomes for Gastroesophageal Cancer

July 18th 2018

FLOT Regimen for Resectable Gastroesophageal Cancer

July 18th 2018

Next-Generation Sequencing for Gastric and GEJ Cancer

July 18th 2018

Gastroesophageal Cancer: Initial Approaches

July 18th 2018

Global Trends in Gastroesophageal Cancer

July 18th 2018

West Coast Study Rates Cancer Centers by Cost and Quality

July 17th 2018

In a groundbreaking study of costs and quality of cancer care among cancer clinics in the state of Washington, investigators found wide disparity in end-of-life care, suggesting that improvements in cost and quality could be attained if treatment centers share information on what works and endeavor to improve.

Dr. Barr on Temozolomide and Capecitabine in Neuroendocrine Tumors

July 17th 2018

Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses the combination of temozolomide and capecitabine in neuroendocrine tumors (NETs).

Dr. Yezefski Compares Costs and Outcomes of Chemotherapy in the US and Canada

July 16th 2018

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, compares the costs and outcomes of chemotherapy in the United States and Canada for patients with colorectal cancer.

Dr. Choti on Updates in Neoadjuvant and Adjuvant Therapy for CRC

July 13th 2018

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses updates in neoadjuvant and adjuvant therapy for patients with colorectal cancer.

FDA Grants Pembrolizumab Priority Review for HCC

July 12th 2018

The FDA has granted a priority review designation to a supplemental biologics license application for pembrolizumab for previously treated patients with advanced hepatocellular carcinoma

Dr. Eng on the FDA Approval of Nivolumab Plus Ipilimumab in CRC

July 11th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer

July 11th 2018

The FDA has approved the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Dr. Ulahannan on the PRODIGE Trial in Pancreatic Cancer

July 11th 2018

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the PRODIGE trial in pancreatic cancer.

Experts Anticipate a Growing Menu of Frontline Options in Liver Cancer

July 4th 2018

Panelists review data for lenvatinib (Lenvima), and novel drugs under investigation in the second line for HCC, such as cabozantinib (Cabometyx/Cometriq) and pembrolizumab (Keytruda).

Marshall Makes the Case for Molecular Sorting in Gastrointestinal Disease

July 3rd 2018

Oncologists have been slow to introduce targeted and immune therapies into the treatment of gastrointestinal cancers, but that is changing, and poor patient survival statistics call for a continuation of this trend, according to John L. Marshall, MD.

Expert Provides Clarity on Treatment of Advanced HCC

June 28th 2018

Mitesh J. Borad, MD, discusses liver-directed therapies, systemic therapy, and the management of liver cancer.